Avid Bioservices Inc (CDMO)

[cjgaddy]

CEO S.King’s 3-10-14 ROTH Talk (DanaPT CA) - Slideshow

Mar9-12 2014: “Roth’s 26th Annual OC Growth Stock Conf.”, DanaPT, CA
http://www.roth.com/main/Page.aspx?PageID=7214

CEO Steven King’s 22 min. Presentation – Roth/DanaPT CA
3-10-2014 1pmPT WEBCAST Replay: http://ir.peregrineinc.com/events.cfm
Direct Replay: http://wsw.com/webcast/roth28/PPHM






















































.
Roth Capital /Joe Pantginis - init. 7-15-10 Buy/PT=$10, CURR: Buy/$5 http://www.roth.com
. . .Universe (click link bottom right): http://roth.bluematrix.com/docs/pdf/BLUE.pdf
. . .6-28-13: Roth lowers PPHM PT 7=>$5 (following PPHM's 6-28-13 press release)
. . .6-3-13: Roth raises PPHM PT 4=>$7 ("ASCOdata+FDA_ph3 agreement & visibility should represent the final potential triggers to conclude a partnership deal.") http://tinyurl.com/kkvddt2
. . .1-14-13: Roth raises PPHM PT 2.70=>$4.00 ("partnering discussions have new found life") http://tinyurl.com/a9t29lb
. . .1-7-13: Roth ups Neutral to BUY, PT 1.25=>$2.70 (after 2nd-Line NSCLC Review Upd) http://tinyurl.com/bfj7mva
. . .12-11-12: Roth ups PT $.70=>$1.25 after Cotara Ph3 design approval & 12-10-12/10Q-CC.
. . .9-24-12: Roth cuts PT $9=>$.70 after PPHM PR about 2nd-Line NSCLC trial data problems.
. . .9-10-12: Roth ups PT $5=>$9 ("highly encouraged by 2ndLine NSCLC clinical data") http://tinyurl.com/9blrqk7
. . .8-15-12: Roth adds PPHM to focus list as a Top Biotech Pick: http://tinyurl.com/9rx5bps
. . .5-21-12: Roth ups PT $3.30=>$5 ("impressed by the strong 2ndLine NSCLC clinical data") http://tinyurl.com/cnghzyv